# Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg

> **NCT06348303** · PHASE4 · COMPLETED · sponsor: **Primus Pharmaceuticals** · enrollment: 20 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Metaxalone m640 mg oral tablet
- **DRUG:** Metaxalone 800 mg oral tablet

## Key facts

- **NCT ID:** NCT06348303
- **Lead sponsor:** Primus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-16
- **Primary completion:** 2024-09-05
- **Final completion:** 2024-10-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06348303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06348303, "Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06348303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*